FIG. 5.

Measured tumor volumes (A) and calculated viable tumor volumes (B) of ¹⁸⁶Re-Doxil (Re+D) (555 MBq/kg, 6.5 mg/kg doxorubicin) compared with ¹⁸⁶Re-PEG-liposomes (Re+L) (1295 MBq/kg), unlabeled Doxil (6.5 mg/kg doxorubicin), and unlabeled PEG-liposomes for 42 days postinjection. The data in B are from histopathological analysis of the tumors obtained at necropsy, which was day 42 for the ¹⁸⁶Re-Doxil and Doxil groups, day 10 for the unlabeled PEG-liposome and control groups, and day 19 for the ¹⁸⁶Re-PEG-liposome group (**p<0.01, ¹⁸⁶Re-Doxil vs. Doxil).